AstraZeneca experienced a significant drop in its market value following the announcement that its heart disease drug, Wainua, failed to meet the primary endpoint in a late-stage clinical trial. The company’s shares fell by as much as 11 percent during early trading, resulting in a decline of more than £20 billion in market capitalization. The stock closed 6.2 percent lower, reaching an eight-month low of 13,354 pence per share.
Wainua, developed in partnership with US-based Ionis Pharmaceuticals, was tested as a treatment for transthyretin-mediated amyloid cardiomyopathy (ATTR-CM), a progressive heart condition affecting an estimated 300,000 to 500,000 patients globally. The phase III trial involved 1,432 patients across 130 sites in 20 countries and assessed whether adding Wainua to the standard of care would reduce cardiovascular mortality and recurring cardiovascular events over approximately 140 weeks. AstraZeneca reported that the drug did not demonstrate a statistically significant benefit on these outcomes compared to placebo.
The setback dampens expectations for Wainua, which AstraZeneca had anticipated could generate more than $5 billion in peak annual sales and help broaden the company’s portfolio beyond its core oncology treatments. The drug is already approved in over 20 countries for a rare nerve disorder and generated $212 million in revenue last year. AstraZeneca acquired the asset through its agreement with Ionis in late 2021.
Company executives emphasized that, despite the trial missing its primary objective, the results contribute valuable scientific insights into treatment for ATTR-CM, a condition with limited therapeutic options. AstraZeneca and Ionis plan to analyze the full data set further and present their findings to the scientific community in August.
The market reaction reflected not only the immediate loss in potential revenue but also concerns about the company’s overall credibility in designing and executing clinical trials, which had previously been a strength. Analysts noted this as a notable blow amid other recent challenges, including regulatory delays in breast cancer drug approvals in the United States.
Despite the setback, analysts remain cautiously optimistic about AstraZeneca’s longer-term prospects. The company maintains its broader goal of achieving $60 billion to $80 billion in annual revenues by 2030, supported by a pipeline of approximately 20 planned drug launches. Chief Executive Pascal Soriot has overseen a transformation of AstraZeneca’s portfolio in recent years, particularly in oncology, and the company recently secured a harmonized listing on stock exchanges in London, New York, and Stockholm to broaden investor access.
Shares of Ionis Pharmaceuticals also fell sharply following the news. While approval for Wainua now appears highly unlikely, AstraZeneca and analysts will await further trial data from upcoming oncology studies before assessing the company’s near-term outlook.